z-logo
Premium
Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers
Author(s) -
Kao JiaHorng,
Chen PeiJer,
Lai MingYang,
Chen DingShinn
Publication year - 2004
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.10534
Subject(s) - virology , seroconversion , genotype , hepatitis b virus , hepatitis , antigen , hepatitis b , medicine , viral disease , virus , biology , immunology , gene , genetics
Hepatitis B virus (HBV) is classified into eight genotypes (A–H), and genotype C is associated with more aggressive liver disease compared to genotype B. However, the mechanisms responsible for the clinical differences remain unclear. To test whether genotype C patients had with lower rates of spontaneous hepatitis B ge antigen (HBeAg) seroconversion than genotype B patients, stored serum samples from 146 Taiwanese adult HBeAg‐positive hepatitis B carriers followed‐up for a mean of 52 months (range, 12–120 months) were tested for HBV genotype by a molecular method. Genotype C patients were significantly older than genotype B patients (mean age, 37 ± 12 vs. 29 ± 10 years, P  < 0.001). During the follow‐up period, genotype C patients had a significantly lower rate of spontaneous HBeAg seroconversion than genotype B patients (27 vs. 47%, P  < 0.025). Spontaneous HBeAg seroconversion occurred one decade later in genotype C patients compared with genotype B patients. Multivariate analyses identified age ≤35 years (odds ratio: 2.08; 95% confidence interval [CI], 1.07–4.0; P  < 0.05), high baseline serum alanine aminotransferase level (odds ratio: 2.34; 95%CI, 1.39–4.09; P  < 0.005), and HBV genotype B (odds ratio: 1.94; 95%CI, 1.03–3.63; P  < 0.05) as independent factors associated with spontaneous HBeAg seroconversion. In conclusion, genotype C patients, compared to genotype B patients, have a delayed HBeAg seroconversion in the immune clearance phase of chronic HBV infection, which may contribute to a more progressive liver disease and more refractory to antiviral therapy. J. Med. Virol. 72:363–369, 2004. © 2004 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom